IM vs subcutaneous injection absorption: what the science says

What did @.gabibrandao actually say?

The caption, not the spoken transcript, carries the real content here. @.gabibrandao claims that intramuscular (IM) injections absorb faster than subcutaneous (SubQ) injections because muscle tissue is more vascularized. The caption states: "O músculo é mais vascularizado (tem mais fluxo de sangue) enquanto o tecido subcutâneo tem absorção mais gradual." Translated: muscle has more blood flow, fat tissue absorbs more gradually. The spoken transcript in this video is incoherent and does not appear to match the caption content at all, so this fact-check is based entirely on the written claims.

The video is tagged with peptides, testosterone, and weight loss hashtags, suggesting the context is peptide or hormone injection protocols, not standard vaccine administration.

Does the science back this up?

On the basic pharmacokinetics claim, yes, mostly. Muscle tissue does have higher perfusion than subcutaneous fat, and this generally produces faster peak plasma concentrations for many compounds. But "faster" does not automatically mean "better" for peptides, and the caption oversimplifies a relationship that varies considerably by molecule.

A 2021 review by Kagan et al. in the Journal of Pharmaceutical Sciences confirmed that subcutaneous depots can be highly variable depending on injection site, local blood flow, and molecular size. For peptides specifically, lymphatic uptake plays a significant role in SubQ absorption, which is not purely a blood-flow story. Large peptides like CJC-1295 (over 3,000 Da) rely substantially on lymphatic transport when given SubQ, meaning the "slower but stable" framing is accurate but incomplete. The mechanism is not just reduced vascularity.

What did they get wrong (or right)?

They got the directional claim right. IM is generally faster to peak; SubQ is generally slower and more sustained. Credit where it is due.

What they got wrong is the implied simplicity. The caption frames this as a clean binary driven by one variable: blood flow. That is an oversimplification with real consequences for peptide users.

• Molecular weight matters. Small peptides behave differently from large ones at the same injection site. A 2019 paper by Richter and Jacobsen in Acta Physiologica showed that molecules above 1,000 Da shift substantially toward lymphatic absorption when given SubQ.
• Injection site matters. SubQ in the abdomen absorbs differently than SubQ in the thigh. IM in the deltoid differs from IM in the glute. The caption treats each route as monolithic.
• For some peptides, SubQ is the preferred clinical route precisely because the slower profile is pharmacologically advantageous, not a compromise. Ipamorelin's pulsatile GH release is better preserved with SubQ administration in most clinical protocols.

The caption also cuts off mid-sentence, so whatever nuance may have followed is missing from the public-facing content.

What should you actually know?

If you are using or considering peptide therapy, the IM-versus-SubQ question is real and worth understanding, but it does not have a universal answer. Route of administration should be matched to the specific compound, the desired pharmacokinetic profile, and guidance from a licensed prescriber.

A few grounded points:

• SubQ is the standard route for most peptide therapies in clinical use, including GLP-1 analogs and most research-context peptides, because the sustained release profile is intentional.
• IM injections carry higher risk of hitting nerves or blood vessels, particularly for self-administration without clinical training.
• Bioavailability differences between routes can affect dosing calculations. Switching routes without adjusting dose or protocol is not a neutral decision.
• No peptide, regardless of injection route, has been approved by the FDA for the indications commonly discussed in this content category. Compounded peptides are not equivalent to any approved drug product.

The caption's core pharmacology is not wrong. But treating it as a practical how-to guide without individualized medical oversight would be a mistake.

Bottom line

This is a basic pharmacokinetics claim that holds up in broad terms but strips away the complexity that actually matters for peptide users. The spoken transcript in the video is gibberish and provides no additional information. The written caption is directionally accurate but oversimplified. If you are making injection route decisions based on a TikTok caption alone, that is the real problem here.